Virax Biolabs announces extraordinary shareholder meeting

A separate vote will seek adoption of amended and restated memorandum and articles of association to reflect the share capital increase.

Another resolution would allow the meeting to be adjourned if more time is needed to secure votes on the proposals.

Virax Biolabs will hold an extraordinary general meeting in Glasgow on Aug. 14, 2026.

Shareholders will vote on increasing authorized share capital to US$12.5 million, or 500,000,000 ordinary shares, from US$50,000, or 2,000,000 shares.